JP2024515319A5 - - Google Patents
Info
- Publication number
- JP2024515319A5 JP2024515319A5 JP2023566450A JP2023566450A JP2024515319A5 JP 2024515319 A5 JP2024515319 A5 JP 2024515319A5 JP 2023566450 A JP2023566450 A JP 2023566450A JP 2023566450 A JP2023566450 A JP 2023566450A JP 2024515319 A5 JP2024515319 A5 JP 2024515319A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- cells
- tumor
- nucleic acid
- expression vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110481979.9 | 2021-04-30 | ||
| CN202110481979 | 2021-04-30 | ||
| PCT/CN2022/090106 WO2022228538A1 (zh) | 2021-04-30 | 2022-04-29 | 一种表达免疫调节因子的car载体及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515319A JP2024515319A (ja) | 2024-04-08 |
| JP2024515319A5 true JP2024515319A5 (https=) | 2025-04-17 |
Family
ID=82862040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566450A Pending JP2024515319A (ja) | 2021-04-30 | 2022-04-29 | 免疫調節因子を発現するｃａｒベクター及びその応用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240325442A1 (https=) |
| JP (1) | JP2024515319A (https=) |
| CN (1) | CN114934071B (https=) |
| AU (1) | AU2022263746A1 (https=) |
| GB (1) | GB2621770B (https=) |
| WO (1) | WO2022228538A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117986387A (zh) * | 2023-05-31 | 2024-05-07 | 四川大学华西医院 | 一种新型小型化car设计及制备方法和应用 |
| CN119144564B (zh) * | 2023-11-24 | 2025-11-25 | 成都赛恩吉诺生物科技有限公司 | 表达GM-CSF的Ahelix功能区的免疫工程细胞及应用 |
| CN119220499B (zh) * | 2023-11-24 | 2025-11-25 | 成都赛恩吉诺生物科技有限公司 | 表达gm-csf的非连续截短功能区的免疫工程细胞及应用 |
| CN119144565B (zh) * | 2023-11-24 | 2025-11-25 | 成都赛恩吉诺生物科技有限公司 | 表达GM-CSF的exon 2功能区的免疫工程细胞及应用 |
| CN119432754B (zh) * | 2023-11-24 | 2025-10-10 | 成都赛恩吉诺生物科技有限公司 | 表达gm-csf的连续截短功能区的免疫工程细胞及应用 |
| CN119144563B (zh) * | 2023-11-24 | 2025-11-25 | 成都赛恩吉诺生物科技有限公司 | 表达gm-csf截短功能区片段的免疫工程细胞及应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2828290B1 (en) * | 2012-03-23 | 2018-08-15 | The United States of America, represented by the Secretary, Department of Health and Human Services | Anti-mesothelin chimeric antigen receptors |
| EP4166148B1 (en) * | 2014-06-06 | 2026-02-18 | Memorial Sloan-Kettering Cancer Center | Mesothelin-targeted chimeric antigen receptors and uses thereof |
| IL315940A (en) * | 2015-07-28 | 2024-11-01 | Univ Pennsylvania | Altered monocytes/macrophages expressing chimeric antigen receptors and their uses |
| CN105505869A (zh) * | 2015-12-21 | 2016-04-20 | 河南大学淮河医院 | 一种针对肿瘤干细胞的嵌合抗原受体t细胞 |
| US20180028631A1 (en) * | 2016-07-29 | 2018-02-01 | Lan Bo Chen | Anti-ssea4 chimeric antigen receptors and their use for treating cancer |
| CN106543288A (zh) * | 2016-10-24 | 2017-03-29 | 山东兴瑞生物科技有限公司 | 一种间皮素嵌合抗原受体修饰的t细胞制备及胰腺癌治疗上的应用 |
| AU2018367452B2 (en) * | 2017-11-14 | 2024-06-13 | Memorial Sloan-Kettering Cancer Center | IL-36 secreting immunoresponsive cells and uses thereof |
| WO2019099479A1 (en) * | 2017-11-14 | 2019-05-23 | Memorial Sloan-Kettering Cancer Center | Il-33 secreting immunoresponsive cells and uses thereof |
| JP7296133B2 (ja) * | 2018-03-16 | 2023-06-22 | 国立大学法人信州大学 | 遺伝子改変細胞及びその作製方法 |
| JP7411578B2 (ja) * | 2018-06-01 | 2024-01-11 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 癌を治療するための物質及び方法 |
| US20220000921A1 (en) * | 2018-11-20 | 2022-01-06 | Innovative Cellular Therapeutics Holdings, Ltd. | Modified Cell Expressing Therapeutic Agent and Uses thereof |
| CN110760001B (zh) * | 2019-07-29 | 2023-03-24 | 浙江启新生物技术有限公司 | Gm-csf敲低及其中和单链抗体分泌的嵌合抗原受体t细胞构建与应用 |
| CN110396131B (zh) * | 2019-08-23 | 2020-07-10 | 北京鼎成肽源生物技术有限公司 | 一种ErbB2单链抗体、靶向人ErbB2的嵌合抗原受体、重组载体、重组细胞和应用 |
| CN110964121B (zh) * | 2019-12-20 | 2022-09-16 | 山东省齐鲁细胞治疗工程技术有限公司 | 一种分泌il-7、il-15因子的cd19-car-t细胞及其应用 |
| CN111944760A (zh) * | 2020-08-14 | 2020-11-17 | 广东先康达生物科技有限公司 | 一种分泌双特异性抗体的免疫细胞及其应用 |
| CN112210018A (zh) * | 2020-10-12 | 2021-01-12 | 广东昭泰体内生物医药科技有限公司 | 一种靶向gpc3的嵌合抗原受体及其应用 |
-
2022
- 2022-04-28 CN CN202210470233.2A patent/CN114934071B/zh active Active
- 2022-04-29 WO PCT/CN2022/090106 patent/WO2022228538A1/zh not_active Ceased
- 2022-04-29 JP JP2023566450A patent/JP2024515319A/ja active Pending
- 2022-04-29 US US18/288,782 patent/US20240325442A1/en active Pending
- 2022-04-29 AU AU2022263746A patent/AU2022263746A1/en active Pending
- 2022-04-29 GB GB2318060.7A patent/GB2621770B/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024515319A5 (https=) | ||
| Lollini et al. | Vaccines for tumour prevention | |
| Kirkwood et al. | Immunotherapy of cancer in 2012 | |
| Li et al. | Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself | |
| Whiteside et al. | Emerging opportunities and challenges in cancer immunotherapy | |
| Kazemi et al. | Immunotherapeutic approaches for cancer therapy: an updated review | |
| Lu et al. | Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor | |
| Hanks et al. | Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo | |
| Janke et al. | Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy | |
| Fuse et al. | Recall responses by helpless memory CD8+ T cells are restricted by the up-regulation of PD-1 | |
| RU2018118817A (ru) | Химерные рецепторы антигена, нацеленные на her2 | |
| JP2019500894A5 (https=) | ||
| Cappello et al. | LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice | |
| US12491201B2 (en) | Maximizing T-cell memory and compositions and methods therefor | |
| Junghans | The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective | |
| JP2019507582A5 (https=) | ||
| JP7812549B2 (ja) | 人工免疫監視キメラ抗原受容体（ａｉ－ｃａｒ）及びそれを発現する細胞 | |
| Ahmad et al. | PD-L1-specific T cells | |
| Gu et al. | Forced co-expression of IL-21 and IL-7 in whole-cell cancer vaccines promotes antitumor immunity | |
| Chen et al. | IL-21-and CXCL9-engineered GPC3-specific CAR-T cells combined with PD-1 blockade enhance cytotoxic activities against hepatocellular carcinoma | |
| Sharma et al. | SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model | |
| JP2022528024A5 (https=) | ||
| Rohrbach et al. | Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity | |
| Asgari et al. | In vitro cytotoxic effect of Trastuzumab in combination with Pertuzumab in breast cancer cells is improved by interleukin-2 activated NK cells | |
| Glitza Oliva et al. | Immunotherapy for melanoma |